nach oben

Die Urologie

Erschienen in:

27.05.2021 | Harnblasenkarzinom | Fallbasierte Leitlinien

Blasenkarzinomsystemtherapie

verfasst von: M. Haas, M. Burger, M. J. Schnabel

Erschienen in: Die Urologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Cisplatin-basierte Polychemotherapie stellt in der Systemtherapie des muskelinvasiven Harnblasenkarzinoms („muscle-invasive bladder cancer“, MIBC) seit langer Zeit den Therapiestandard dar. In den vergangenen Jahren haben sich zudem auch Immun-Checkpoint-Inhibitoren (ICI) als Therapiealternative bei Cisplatin-ungeeigneten Patienten und in der Therapiesequenz des metastasierten Urothelkarzinoms etabliert. In diesem Artikel sollen die verfügbare Literatur und aktuelle Leitlinien anhand von zwei Patientenbeispielen aufgearbeitet werden, um so Therapieentscheidungen und Behandlungspfade in der Systemtherapie des lokal begrenzten und metastasierten Urothelkarzinoms der Harnblase aufzuzeigen und praxisrelevante Inhalte zu vermitteln.

Gesellschaft der epidemiologischen Krebsregister in Deutschland (2021) Atlas der Krebsinzidenz und -mortalität in Deutschland (GEKID-Atlas). https://atlas.gekid.de/CurrentVersion/atlas.html. Zugegriffen: 21. Febr. 2021

Stenzl A, Penkoff H, Dajc-Sommerer E et al (2011) Detection and clinical outcome of urinary bladder cancer with 5‑aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117(5):938–947. https://doi.org/10.1002/cncr.25523CrossRefPubMed

Geavlete B, Multescu R, Georgescu D et al (2012) Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: Does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109(4):549–556. https://doi.org/10.1111/j.1464-410X.2011.10374.xCrossRefPubMed

Mowatt G, N’Dow J, Vale L et al (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 27(1):3–10. https://doi.org/10.1017/S0266462310001364CrossRefPubMed

Kausch I, Sommerauer M, Montorsi F et al (2010) Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 57(4):595–606. https://doi.org/10.1016/j.eururo.2009.11.041CrossRefPubMed

Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q (2012) Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 110(11 Pt B):E680–E687. https://doi.org/10.1111/j.1464-410X.2012.11500.xCrossRefPubMed

Drejer D, Béji S, Munk Nielsen A et al (2017) Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa‑7 study. Scand J Urol 51(2):120–123. https://doi.org/10.1080/21681805.2017.1295101CrossRefPubMed

Naito S, Algaba F, Babjuk M et al (2016) The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1‑year results. Eur Urol 70(3):506–515. https://doi.org/10.1016/j.eururo.2016.03.053CrossRefPubMed

Kim SB, Yoon SG, Tae J et al (2018) Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy. Investig Clin Urol 59(2):98–105. https://doi.org/10.4111/icu.2018.59.2.98CrossRefPubMedPubMedCentral

10.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3 Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, AWMF-Registrierungsnummer 032/038O. https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom. Zugegriffen: 21. Febr. 2021

11.

Kitamura H, Tsukamoto T, Shibata T et al (2014) Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol 25(6):1192–1198. https://doi.org/10.1093/annonc/mdu126CrossRefPubMed

12.

Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506–513. https://doi.org/10.1002/cncr.22031CrossRefPubMed

13.

Galsky MD, Chen GJ, Oh WK et al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23(2):406–410. https://doi.org/10.1093/annonc/mdr156CrossRefPubMed

14.

Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29:2432–2438CrossRef

15.

Mead GM, Russell M, Clark P et al (1998) A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78(8):1067–1075. https://doi.org/10.1038/bjc.1998.629CrossRefPubMedPubMedCentral

16.

Milosevic M et al (2007) Radiotherapy for bladder cancer. Urology 69:80–92CrossRef

17.

Ploussard G et al (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 66:120–137CrossRef

18.

Efstathiou JA et al (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705–711CrossRef

19.

James ND et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488CrossRef

20.

Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039–1047. https://doi.org/10.1016/j.eururo.2012.02.028CrossRefPubMed

21.

Rödel C et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071CrossRef

22.

Abdollah F, Sun M, Schmitges J et al (2012) Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int 109(8):1147–1154. https://doi.org/10.1111/j.1464-410X.2011.10482.xCrossRefPubMed

23.

Hautmann RE, Gschwend JE, de Petriconi RC et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176(2):486–492. https://doi.org/10.1016/j.juro.2006.03.038CrossRefPubMed

24.

Kaimakliotis HZ et al (2020) Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): interim results from the cisplatin (C)-ineligible cohort of GU14-188. J Clin Oncol 38:5019CrossRef

25.

Van Dijk N et al (2020) Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO). J Clin Oncol 38:5020CrossRef

26.

Necchi A et al (2021) SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy. J Clin Oncol 39(suppl 6):TPS506CrossRef

27.

Galsky MD et al (2021) Keynote-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol 39(suppl 6):TPS507CrossRef

28.

Powles T et al (2019) A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+ cisplatin (G+ C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC)(NIAGARA). J Clin Oncol 37(15_suppl):TPS4592CrossRef

29.

Bajorin DF et al (2021) First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 39(suppl 6):391CrossRef

30.

Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12):2448–2458. https://doi.org/10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7CrossRefPubMed

31.

Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M‑VAC chemotherapy and G‑CSF versus classic M‑VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54. https://doi.org/10.1016/j.ejca.2005.08.032CrossRefPubMed

32.

Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10):2638–2646. https://doi.org/10.1200/JCO.2001.19.10.2638CrossRefPubMed

33.

von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757CrossRefPubMed

34.

Hussain SA, Stocken DD, Riley P et al (2004) A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91(5):844–849. https://doi.org/10.1038/sj.bjc.6602112CrossRefPubMedPubMedCentral

35.

Hussain SA, Palmer DH, Lloyd B et al (2012) A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 3(4):855–859. https://doi.org/10.3892/ol.2012.563CrossRefPubMedPubMedCentral

36.

De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191–199. https://doi.org/10.1200/JCO.2011.37.3571CrossRefPubMed

37.

Powles T et al (2020) Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol 38:LBA1CrossRef

38.

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683CrossRefPubMedPubMedCentral

39.

Bellmunt J, Théodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461. https://doi.org/10.1200/JCO.2008.20.5534CrossRefPubMed

40.

Bellmunt J, Fougeray R, Rosenberg JE et al (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24(6):1466–1472. https://doi.org/10.1093/annonc/mdt007CrossRefPubMed

41.

Sonpavde G, Pond GR, Choueiri TK et al (2016) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69(4):634–641. https://doi.org/10.1016/j.eururo.2015.07.042CrossRefPubMed

42.

Galsky MD et al (2021) A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). J Clin Oncol 39(suppl 6):TPS504CrossRef

43.

Grivas P et al (2021) TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J Clin Oncol 39(suppl 6):TPS498CrossRef

44.

Rosenberg JE et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 37:2592–2600CrossRef

45.

Petrylak DP et al (2019) EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). J Clin Oncol 37:TPS497CrossRef

Titel: Blasenkarzinomsystemtherapie
verfasst von: M. Haas
M. Burger
M. J. Schnabel
Publikationsdatum: 27.05.2021
Verlag: Springer Medizin
Schlagwörter: Harnblasenkarzinom
Harnblasenkarzinom
Metastasen
Urothelkarzinom
Zystektomie
Urothelkarzinom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Zytostatische Therapie
Erschienen in: Die Urologie / Ausgabe 9/2021
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-021-01535-3

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

Mit dem Update der Clinical Practice Guidelines 2023 zum metastasierenden nicht-kleinzelligen Lungenkarzinom (mNSCLC) trägt die ESMO der in den letzten Jahren immer weiter gewachsenen Anzahl an Therapieoptionen Rechnung.

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Mit NOVUM Onkologie veranstaltet MSD regelmäßig Online-Fortbildungen zum Thema Lungenkarzinom. Bei dem mittlerweile etablierten Format erhalten Teilnehmende die Möglichkeit sich bei Expertendiskussionen zu praxisrelevanten Themen der pneumologischen Onkologie weiterzubilden.

Fokus Immunonkologie – NSCLC

Content Hub

Die Einführung von Immun-Checkpoint-Inhibitoren markierte einen entscheidenden Fortschritt in der Behandlung von bestimmten Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer, NSCLC) und eröffnete seither neue Perspektiven und Chancen für Behandler und geeignete Patienten. Hier finden Sie fortlaufend aktuelle Informationen und relevante Beiträge zur Immunonkologie in dieser Indikation.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

CME: Laser in der Urologie – relevante Grundlagen

LUTS infolge einer BPH: Kombinationstherapie auf dem Prüfstand

Digitale Transformation in der Urologie – Chance, Risiko oder Notwendigkeit?

Berufspolitik BvDU

Termine

GeSRU

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Fokus Immunonkologie – NSCLC